Success Metrics

Clinical Success Rate
50.0%

Based on 3 completed trials

Completion Rate
50%(3/6)
Active Trials
0(0%)
Results Posted
67%(2 trials)
Terminated
3(50%)

Phase Distribution

Ph phase_2
1
17%
Ph phase_1
5
83%

Phase Distribution

5

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
5(83.3%)
Phase 2Efficacy & side effects
1(16.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

3 of 6 finished

Non-Completion Rate

50.0%

3 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(3)
Terminated(3)

Detailed Status

Completed3
Terminated3

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
50.0%
Most Advanced
Phase 2

Trials by Phase

Phase 15 (83.3%)
Phase 21 (16.7%)

Trials by Status

completed350%
terminated350%

Recent Activity

0 active trials
Showing 5 of 6
terminatedphase_1

Phase I, Open-label, Dose Escalation of AZD4877 in Hematologic Malignancies

NCT00460460
completedphase_2

A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer

NCT00661609
terminatedphase_1

Phase I/II, Open-label, Multi-center, Two Part Dose-escalation, Safety, Pharmacokinetics (PK) and Efficacy Study of AZD4877 in Patients With Acute Myelogenous Leukemia (AML)

NCT00486265
terminatedphase_1

Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD4877

NCT00471367
completedphase_1

A Phase I, Dose-Escalation Study to Assess the Safety and Drug Levels in Blood of AZD4877 in Japanese Adult Patients

NCT00613652
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT00460460Phase 1

Phase I, Open-label, Dose Escalation of AZD4877 in Hematologic Malignancies

Terminated
NCT00661609Phase 2

A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer

Completed
NCT00486265Phase 1

Phase I/II, Open-label, Multi-center, Two Part Dose-escalation, Safety, Pharmacokinetics (PK) and Efficacy Study of AZD4877 in Patients With Acute Myelogenous Leukemia (AML)

Terminated
NCT00471367Phase 1

Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD4877

Terminated
NCT00613652Phase 1

A Phase I, Dose-Escalation Study to Assess the Safety and Drug Levels in Blood of AZD4877 in Japanese Adult Patients

Completed
NCT00389389Phase 1

Phase I, Open-Label, Dose-Escalation Study of AZD4877 in Solid Tumors

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6